Liquidia expands Pharmosa L606 license to Europe and Japan for $3.5 million upfront
On October 2, 2024, Liquidia Technologies, a wholly owned subsidiary of Liquidia Corporation, amended its license with Pharmosa Biopharm to extend the rights to L606 beyond North America to markets including Europe and Japan. The companies also signed a Device License Agreement giving Liquidia exclusive rights to Pharmosa's next-generation nebulizers for use with L606 in most countries. The filing says Liquidia will pay $3.5 million upfront and up to $157.75 million in potential milestones, with royalty terms unchanged, but it does not report any revenue or profit effect.
Key points
- Upfront payment of $3.5 million due within 30 days after Liquidia Technologies receives Pharmosa's invoice following the October 2, 2024 Effective Date
- Up to $7.75 million in development milestones and up to $150 million in sales milestones, both tied to activity outside North America
- Pharmosa retains China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia; royalties on global net sales are unchanged
- Full text of the First Amendment and Device License Agreement will be filed as exhibits to the next Form 10-Q
The filing
Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.